Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HDR003
MIFTS: 50

Hidradenitis

Categories: Endocrine diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hidradenitis

About this section

MalaCards integrated aliases for Hidradenitis:

Name: Hidradenitis 11 43 14 71 75
Hydradenitis 11

Classifications:

MalaCards categories:
Anatomical: Skin diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:2282
ICD9CM 34 705.83
MeSH 43 D016575
NCIt 49 C112190
SNOMED-CT 68 267866004
UMLS 71 C0085160
Sources

Summaries for Hidradenitis

About this section

Disease Ontology: 11 A sweat gland disease that is characterized by inflammation of the apocrine sweat glands and has symptom erythema, edema, papules, plaques, pruritis, and pain.

MalaCards based summary: Hidradenitis, also known as hydradenitis, is related to pyogenic sterile arthritis, pyoderma gangrenosum, and acne and dowling-degos disease, and has symptoms including erythema An important gene associated with Hidradenitis is NCSTN (Nicastrin), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Triamcinolone and Anesthetics have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

Wikipedia: 75 Hidradenitis is any disease in which the histologic abnormality is primarily an inflammatory infiltrate... more...
Sources

Related Diseases for Hidradenitis

About this section

Diseases related to Hidradenitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 890)
# Related Disease Score Top Affiliating Genes
1 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 31.7 PSTPIP1 NLRP3 MEFV IL1B
2 dowling-degos disease 31.1 PSENEN PSEN1 NCSTN
3 inflammatory bowel disease 1 31.0 TNF NOD2 IL1B IL17A
4 folliculitis 31.0 TNF IL17A IFNG
5 spondyloarthropathy 1 30.9 TNF NOD2 IL1B IL17A CRP
6 pyoderma gangrenosum 30.9 TNF PSTPIP1 NOD2 NLRP3 MEFV IL1B
7 cellulitis 30.7 TNF IL1B IL17A CRP CAMP
8 bowel dysfunction 30.7 TNF NOD2 LCN2 IL1B CRP
9 chronic ulcer of skin 30.6 TNF IL1B CRP
10 synovitis 30.5 TNF IL1B IL1A CRP
11 serum amyloid a amyloidosis 30.5 TNF NLRP3 MEFV CRP
12 hidradenitis suppurativa 30.5 TNF S100A7 PSTPIP1 PSENEN PSEN1 NOD2
13 sapho syndrome 30.5 TNF PSTPIP1 NOD2 IL17A CRP
14 arthropathy 30.5 TNF NOD2 NLRP3 IL1B CRP
15 reactive arthritis 30.5 TNF IL17A CRP
16 amyloidosis 30.5 TNF PSEN1 NLRP3 MEFV IL1B CRP
17 acne 30.5 TNF S100A7 PSTPIP1 PSENEN PSEN1 NLRP3
18 autoinflammatory syndrome 30.5 NOD2 NLRP3 MEFV
19 crohn's disease 30.4 TNF NOD2 NLRP3 IL26 IL1B IL17A
20 alopecia 30.4 TNF IL1B IL1A IL17A IFNG
21 keratitis, hereditary 30.4 TNF NLRP3 IL1B IL17A GJB2
22 osteoarthritis 30.4 TNF IL1B IL1A IL17A CRP
23 covid-19 30.4 TNF NLRP3 IL1B CRP
24 ulcerative colitis 30.3 TNF NOD2 IL1B IL17A IFNG CRP
25 fibromyalgia 30.3 TNF IL1B CRP
26 psoriasis 30.3 TNF S100A7 NOD2 IL1B IL1A IL17A
27 substance abuse 30.3 TNF IL1B CRP
28 pyoderma 30.3 TNF PSTPIP1 NOD2 NLRP3 MEFV IL1B
29 apnea, obstructive sleep 30.3 TNF IL1B CRP
30 psoriatic arthritis 30.3 TNF NOD2 IL1B IL1A IL17A CRP
31 spondylitis 30.3 TNF NOD2 IL1B IL17A IFNG CRP
32 alopecia areata 30.2 TNF IL1B IL1A IL17A IFNG
33 rosacea 30.2 TNF IL1B IL17A CRP CAMP
34 histiocytosis 30.2 TNF IL17A IFNG
35 interstitial keratitis 30.2 TNF CRP
36 irritable bowel syndrome 30.2 TNF IL1B IL17A CRP
37 pityriasis rubra pilaris 30.2 TNF PSTPIP1 IL17A
38 erythema nodosum 30.2 TNF NOD2 IL1B IL1A IFNG CRP
39 alcohol use disorder 30.1 TNF IL1B CRP
40 fatty liver disease 30.1 TNF IL1B IL1A CRP
41 sleep disorder 30.1 TNF IL1B CRP
42 neutrophilic dermatosis, acute febrile 30.1 TNF PSTPIP1 MEFV IL1B IL17A CRP
43 vasculitis 30.1 TNF MEFV LCN2 IL1B IL17A CRP
44 scleritis 30.1 TNF IFNG CRP
45 spondyloarthropathy 30.1 TNF NOD2 MEFV IL1B IL17A IFNG
46 brucellosis 30.1 TNF NLRP3 MEFV IL17A IFNG CRP
47 seborrheic dermatitis 30.1 TNF IL1A IL17A DSG1
48 lymphangioma 30.1 TNF IL1B IL17A IFNG
49 common cold 30.1 TNF IL1B IL17A CRP
50 acquired immunodeficiency syndrome 30.1 TNF IL1B IFNG CRP

Graphical network of the top 20 diseases related to Hidradenitis:



Diseases related to Hidradenitis
Sources

Symptoms & Phenotypes for Hidradenitis

About this section

Symptoms:

11
  • • erythema

GenomeRNAi Phenotypes related to Hidradenitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 CAMP CRP DSG1 GJB2 IFNG IL12RB1
2 no effect GR00402-S-2 10.19 CAMP CRP DSG1 IFNG IL12RB1 IL1A
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.07 IL17A IL1A IL1B LCN2 NLRP3 TNF
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.07 IL17A IL1B LCN2 NLRP3 NOD2 PSEN1

MGI Mouse Phenotypes related to Hidradenitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 CRP DSG1 GJB2 IFNG IL12RB1 IL17A
2 immune system MP:0005387 10.16 CAMP CRP GJB2 IFNG IL12RB1 IL17A
3 skeleton MP:0005390 9.9 DSG1 GJB2 IFNG IL17A IL1B MEFV
4 hematopoietic system MP:0005397 9.83 CAMP DSG1 IFNG IL12RB1 IL17A IL1A
5 integument MP:0010771 9.4 DSG1 GJB2 IFNG IL12RB1 IL17A IL1A
Sources

Drugs & Therapeutics for Hidradenitis

About this section

Drugs for Hidradenitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2 Anesthetics Phase 4
3
Triamcinolone hexacetonide Phase 4
4
Triamcinolone diacetate Phase 4
5
Triamcinolone Acetonide Phase 4 6436
6 glucocorticoids Phase 4
7 Immunologic Factors Phase 4
8 Immunosuppressive Agents Phase 4
9
Metformin Approved Phase 3 1115-70-4, 657-24-9 4091
10
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
11 Hypoglycemic Agents Phase 3
12 Anti-Bacterial Agents Phase 3
13 Antibiotics, Antitubercular Phase 3
14
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
15
Apremilast Approved, Investigational Phase 2 608141-41-9 10151715 11561674
16
Infliximab Approved Phase 2 170277-31-3
17
Ustekinumab Approved, Investigational Phase 2 815610-63-0
18
Etanercept Approved, Investigational Phase 2 185243-69-0
19
Upadacitinib Approved, Investigational Phase 2 1310726-60-3 76829165 58557659
20
Tofacitinib Approved, Investigational Phase 2 477600-75-2 9926791
21
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
22
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
23
Methylene blue Approved, Investigational Phase 2 61-73-4 6099
24
Gentian violet cation Approved Phase 2 14426-25-6, 7438-46-2 3468 11057
25
Glycerin Approved, Investigational Phase 2 56-81-5 753
26
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
27
Ethinylestradiol Approved Phase 2 57-63-6 5991
28
Polyestradiol phosphate Approved Phase 2 28014-46-2
29
Drospirenone Approved Phase 2 67392-87-4 68873
30
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
31
Lysine Approved, Nutraceutical Phase 2 56-87-1 5962
32
PF-06700841 Investigational Phase 2 1883299-62-4 118878093
33
Vilobelimab Investigational Phase 2 2250440-41-4
34 Antiprotozoal Agents Phase 1, Phase 2
35 Antiparasitic Agents Phase 1, Phase 2
36 Antimalarials Phase 1, Phase 2
37 Complement System Proteins Phase 2
38 Analgesics Phase 2
39 Phosphodiesterase Inhibitors Phase 2
40 Phosphodiesterase 4 Inhibitors Phase 2
41 Anti-Inflammatory Agents, Non-Steroidal Phase 2
42 Analgesics, Non-Narcotic Phase 2
43 Gastrointestinal Agents Phase 2
44 Interleukin 1 Receptor Antagonist Protein Phase 2
45 Protein Kinase Inhibitors Phase 2
46 interferons Phase 2
47 Janus Kinase Inhibitors Phase 2
48 Immunoglobulins Phase 2
49 Antibodies, Monoclonal Phase 2
50 Antibodies Phase 2

Interventional clinical trials:

(show top 50) (show all 155)
# Name Status NCT ID Phase Drugs
1 Cost-effectiveness of Adalimumab With Adjuvant Surgery Versus Adalimumab Monotherapy in the Treatment of Hidradenitis Suppurativa' Unknown status NCT03221621 Phase 4 Adalimumab Injection
2 A Phase 4, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02808975 Phase 4 Placebo;Adalimumab
3 A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions Not yet recruiting NCT05477225 Phase 4
4 Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa Terminated NCT04582669 Phase 4 Intralesional Triamcinolone 10 mg/mL;Intralesional Triamcinolone 20 mg/mL;Intralesional Triamcinolone 40 mg/mL;Placebo
5 Hidradenitis Suppurativa Patients' Experience of Treatment With Adalimumab Withdrawn NCT04132388 Phase 4 Adalimumab
6 Spironolactone in the Treatment of Hidradenitis Suppurativa: A Prospective, Open-Label Proof-of-Concept and Dose-Ranging Study Withdrawn NCT04100083 Phase 4 Spironolactone 50 MG;Spironolactone 100mg;Spironolactone 200 mg
7 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Completed NCT04242498 Phase 3 Bimekizumab
8 A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE) Completed NCT03713632 Phase 3 Secukinumab;Placebo
9 A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE). Completed NCT03713619 Phase 3 secukinumab;Placebo
10 A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension) Completed NCT01635764 Phase 3
11 A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02904902 Phase 3 adalimumab
12 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I Completed NCT01468207 Phase 3
13 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II Completed NCT01468233 Phase 3
14 A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT04179175 Phase 3 secukinumab
15 A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
16 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT04242446 Phase 3 Bimekizumab
17 A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Enrolling by invitation NCT04901195 Phase 3 Bimekizumab
18 Rediscovery of Metformin for the Chronic Disabling Auto-inflammatory Disease Hidradenitis Suppurativa Not yet recruiting NCT04649502 Phase 3
19 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa Not yet recruiting NCT05620836 Phase 3 Povorcitinib;Placebo
20 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa Not yet recruiting NCT05620823 Phase 3 Povorcitinib;Placebo
21 To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
22 An Open-label Single Center Study to Evaluate the Efficacy of SILIQâ„¢ (Brodalumab) for the Treatment of Moderate Hidradenitis Suppurativa Unknown status NCT03910803 Phase 2 Brodalumab
23 Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial Unknown status NCT04061395 Phase 2
24 Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Completed NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
25 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT04019041 Phase 2 bermekimab;placebo
26 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
27 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03926169 Phase 2 Risankizumab;Placebo for risankizumab
28 A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
29 Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
30 An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
31 A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA Completed NCT04092452 Phase 2 PF-06650833;PF-06700841;PF-06826647;Placebo
32 Proof of Concept Study on LTX-109 as Treatment for Hidradenitis Suppurativa Completed NCT04756336 Phase 1, Phase 2 LTX-109 gel, 3% w/w
33 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03852472 Phase 2 Avacopan
34 Randomized, Double-blind, Placebo-controlled, Study of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT04762277 Phase 2 Spesolimab;Placebo
35 A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy Completed NCT02643654 Phase 2 MABp1;Placebo
36 Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
37 A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica) Completed NCT01704534 Phase 2 Ustekinumab
38 A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2 Placebo
39 A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa Completed NCT00107991 Phase 2 etanercept
40 A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03607487 Phase 2 INCB054707;Placebo
41 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT04430855 Phase 2 Upadacitinib;Placebo Upadacitinib
42 A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
43 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
44 A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
45 A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
46 A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03248531 Phase 2 Bimekizumab;Adalimumab
47 A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03569371 Phase 2 INCB054707
48 A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
49 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03487276 Phase 2 IFX-1;Placebo
50 An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra

Search NIH Clinical Center for Hidradenitis

Cochrane evidence based reviews: hidradenitis

Sources

Genetic Tests for Hidradenitis

About this section
Sources

Anatomical Context for Hidradenitis

About this section

Organs/tissues related to Hidradenitis:

MalaCards : Skin, Neutrophil, Liver, Myeloid, Breast, Lymph Node, B Cells
Sources

Publications for Hidradenitis

About this section

Articles related to Hidradenitis:

(show top 50) (show all 4059)
# Title Authors PMID Year
1
Impact of etiology leading to abdominoperineal resection with anterolateral thigh flap reconstruction: A retrospective cohort study. 62
36112361 2023
2
Menopause, skin and common dermatoses. Part 2: skin disorders. 62
35727900 2022
3
Drug survival of Adalimumab biosimilar vs Adalimumab originator in Hidradenitis Suppurativa: can equivalence be assumed? A retrospective cohort study. 62
36461770 2022
4
Patient perspectives on diagnosis and management of hidradenitis suppurativa: A web-based survey. 62
36311912 2022
5
Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa. 62
36054650 2022
6
A survey of dermatologist perspectives on disease management of patients with hidradenitis suppurativa. 62
36237848 2022
7
Association of hidradenitis suppurativa and liver disease: A systematic review and meta-analysis. 62
36248209 2022
8
Effects of mixed-technology CO2 and Ga-As laser in patients with hidradenitis suppurativa-A case series. 62
36457941 2022
9
Hidradenitis suppurativa: racial and socioeconomic considerations in management. 62
35333408 2022
10
Perspectives of obstetricians/gynecologists on hidradenitis suppurativa care: a survey study. 62
36419800 2022
11
Novel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report. 62
36468954 2022
12
A review of how pain is measured in painful skin conditions and rheumatoid arthritis studies, to determine pain measurement in future hidradenitis suppurativa trials. 62
36464931 2022
13
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. 62
36056741 2022
14
Fast-growing mass in a patient with hidradenitis suppurativa. 62
35470548 2022
15
Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study. 62
35934210 2022
16
Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa. 62
35962565 2022
17
Exploring the role of systemic immune-inflammation index and neutrophil-lymphocyte ratio in cardiovascular risk stratification for patients with hidradenitis suppurativa: A cross-sectional study. 62
36000267 2022
18
Low predictive value of questionnaire-based diagnosis of hidradenitis suppurativa. 62
35870150 2022
19
Neighborhood-based analysis of adolescent hidradenitis suppurativa prevalence in a large metropolitan area. 62
36248206 2022
20
Human skin microbiota in health and disease: The cutaneous communities' interplay in equilibrium and dysbiosis: The cutaneous communities' interplay in equilibrium and dysbiosis. 62
34919288 2022
21
This Month in JAAD Case Reports: December 2022. Hidradenitis suppurative and malignancy. 62
36152695 2022
22
Evolving utility of apremilast in dermatological disorders for off-label indications. 62
35974705 2022
23
Self-disgust in Patients with Dermatological Diseases. 62
35113320 2022
24
Interpretation of comorbidity risk in hidradenitis suppurativa: comparing odds ratio and 'number needed to be exposed'. 62
35793407 2022
25
Patterns of Surgical Recurrence in Patients with Hidradenitis Suppurativa. 62
36470224 2022
26
Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases. 62
36346551 2022
27
Neutrophilic dermatoses. 62
35870984 2022
28
Neutrophilic eccrine hidradenitis in a pediatric patient with acute myeloid leukemia. 62
36112359 2022
29
Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab. 62
36006169 2022
30
Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color. Part II: Differences in clinical presentation and disparities in cutaneous disorders in skin of color. 62
35817332 2022
31
Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color - Part I: Genetic, biologic, and structural differences in skin of color. 62
35809800 2022
32
Systemic AA amyloidosis in hidradenitis suppurativa: Should we be screening? 62
36463423 2022
33
Effect of hidradenitis suppurativa on obstetric and neonatal outcomes. 62
35135394 2022
34
Stress signalling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa. 62
35881108 2022
35
Clostridium difficile infection risk in patients with hidradenitis suppurativa. 62
35700148 2022
36
Potential use of microwave technology in dermatology. 62
35699665 2022
37
Methylated miRNAs may serve as potential biomarkers and therapeutic targets for hidradenitis suppurativa. 62
35921387 2022
38
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa'. 62
35727206 2022
39
The Skin and Gut Microbiome in Hidradenitis Suppurativa: Current Understanding and Future Considerations for Research and Treatment. 62
36116091 2022
40
Hidradenitis suppurativa and inflammatory bowel disease in a nested case-control study. 62
36371384 2022
41
Comorbid diseases of hidradenitis suppurativa: a 15-year population-based study in Olmsted County, Minnesota, USA. 62
35485975 2022
42
The impact of hidradenitis suppurativa on quality of life is worse than inflammatory bowel disease and myocardial infarction. 62
35932467 2022
43
Hyperthyroidism and hypothyroidism in patients with hidradenitis suppurativa: a systematic review and meta-analysis. 62
36331091 2022
44
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: Classification: Epidemiology. 62
35718888 2022
45
Psoriasis and hidradenitis suppurativa are associated with inflammatory bowel disease: a growing body of evidence. 62
35975655 2022
46
Massive squamous cell carcinoma arising from hidradenitis suppurativa with marked hypercalcemia and neutrophilia. 62
36186407 2022
47
Modulation of keratin deposition and pathogenesis of hidradenitis suppurativa: evidence coming from pachyonychia congenita. 62
35996837 2022
48
Concurrent Interstitial Granulomatous Dermatitis and TNF-α Antagonist-Induced Lupus Syndrome Secondary to Adalimumab for Crohn's Disease. 62
36342727 2022
49
Hidradenitis suppurativa and sleep: a systematic review. 62
36396891 2022
50
Defining patient-centered research priorities in pediatric dermatology. 62
36443263 2022
Sources

Variations for Hidradenitis

About this section
Sources

Expression for Hidradenitis

About this section
Search GEO for disease gene expression data for Hidradenitis.
Sources

Pathways for Hidradenitis

About this section

Pathways related to Hidradenitis according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.81 TNF PSENEN PSEN1 NCSTN IL26 IL1B
2
Disease 66
Show member pathways
 13.79 PSTPIP1 PSENEN PSEN1 NOD2 NLRP3 NCSTN
3
Cytokine Signaling in Immune system 66
Show member pathways
 13.27 TNF NOD2 LCN2 IL26 IL1B IL1A
4
Innate Immune System 66
Show member pathways
 13.13 TNF S100A7 PSTPIP1 PSEN1 NOD2 NLRP3
5
Alzheimer's disease and miRNA effects 74
Show member pathways
 12.82 TNF PSENEN PSEN1 NCSTN IL1B IL1A
6
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.62 TNF IL1B IL1A IL17A IL12RB1 IFNG
7
Immune response IL-23 signaling pathway 22
Show member pathways
 12.57 TNF IL1B IL17A IL12RB1 IFNG
8
Toll-Like receptor Signaling Pathways 65
Show member pathways
 12.5 TNF NOD2 NLRP3 IL1B
9
Bacterial infections in CF airways 22
Show member pathways
 12.4 TNF IL1B IL1A IFNG
10
Toll Comparative Pathway 64
Show member pathways
 12.3 TNF IL1B IL1A IFNG
11
T-cell activation SARS-CoV-2 74
Show member pathways
 12.13 TNF IL17A IL12RB1 IFNG
12
Neuroinflammation and glutamatergic signaling 74
12.09 IFNG IL1A IL1B TNF
13
Development Notch Signaling Pathway 22
Show member pathways
 12 PSENEN PSEN1 NCSTN IL1A
14
Spinal cord injury 74
11.98 TNF IL1B IL1A IFNG
15
Interleukin-4 and Interleukin-13 signaling 66
11.93 TNF LCN2 IL1B IL1A IL17A
16
Inflammasomes 66
Show member pathways
 11.9 IL1A IL1B MEFV NLRP3 PSTPIP1
17
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 66
Show member pathways
 11.87 PSTPIP1 NOD2 NLRP3 MEFV
18
IL27-mediated signaling events 61
Show member pathways
 11.85 TNF IL1B IL17A IL12RB1 IFNG
19
Activation of NF-KappaB by PKR 64
Show member pathways
 11.78 TNF NLRP3 IL1B IFNG
20
Allograft rejection 74
11.77 TNF IL1B IL1A IL17A IFNG
21
Signaling by NOTCH3 66
Show member pathways
 11.74 PSENEN PSEN1 NCSTN
22
Dendritic Cells Developmental Lineage Pathway 65
11.74 TNF IL1B IFNG
23
Extrafollicular B cell activation by SARS-CoV-2 74
11.72 TNF IFNG CRP
24
Th17 cell differentiation pathway 74
11.71 IFNG IL17A IL1B
25
p75(NTR)-mediated signaling 61
Show member pathways
 11.68 PSENEN PSEN1 NCSTN
26
Th17 Differentiation 65
Show member pathways
 11.68 IL26 IL1B IL17A IL12RB1 IFNG
27
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.67 TNF IL1B IL1A IFNG
28
miRNAs involvement in the immune response in sepsis 74
11.65 TNF LCN2 IL1A
29
IL 10 signaling pathway 67
11.64 TNF IL1B IL1A
30
DYRK1A 74
11.64 PSENEN PSEN1 NCSTN
31
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.56 CAMP IFNG NOD2 TNF
32
Innate Lymphoid Cells Differentiation 65
11.56 IFNG IL12RB1 IL17A IL1B TNF
33
MSP-RON Signaling 64
11.52 IFNG IL1B TNF
34
Interleukin-10 signaling 66
11.51 TNF IL1B IL1A
35
Presenilin action in Notch and Wnt signaling 61
11.5 PSENEN PSEN1 NCSTN
36
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.48 TNF IL1B IL1A IFNG
37
Nucleotide-binding oligomerization domain (NOD) pathway 74
11.42 NOD2 NLRP3 MEFV IL1B
38
IL-10 Pathway 64
11.35 TNF IL1B IL1A
39
Inflammatory bowel disease signaling 74
Show member pathways
 11.32 TNF NOD2 IL1A IL12RB1 IFNG
40
Development and heterogeneity of the ILC family 74
11.24 TNF IL1B IL17A IFNG
41
Immune infiltration in pancreatic cancer 74
11.22 IFNG IL17A TNF
42
IL1 and megakaryocytes in obesity 74
11.16 NLRP3 IL1B IFNG
43
A-beta Plaque Formation and APP Metabolism 65
11.14 PSENEN PSEN1 NCSTN
44
Cytokines and inflammatory response 74
11.13 TNF IL1B IL1A IFNG
45
Syndecan-3-mediated signaling events 61
11.06 PSENEN PSEN1 NCSTN
46
G-protein signaling_Rap2B regulation pathway 22
11.01 TNF IL26 IL1B IL1A IL17A
47
Prostaglandin signaling 74
10.8 TNF NLRP3 IL1B IL1A IL17A
48
Inclusion body myositis 74
10.73 PSENEN PSEN1 NCSTN
49
Activation of NLRP3 inflammasome by SARS-CoV-2 74
10.53 NLRP3 IL1B
50
Notch Pathway 70
10.37 PSENEN PSEN1
Sources

GO Terms for Hidradenitis

About this section

Cellular components related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete integral component of presynaptic membrane GO:0099056 9.13 PSENEN PSEN1 NCSTN
2 gamma-secretase complex GO:0070765 9.1 PSENEN PSEN1 NCSTN

Biological processes related to Hidradenitis according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.48 TNF PSEN1 IL1B IL1A IFNG CRP
2 apoptotic process GO:0006915 10.4 IFNG IL17A IL1A IL1B LCN2 NLRP3
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.36 IL1A IL26 NOD2 S100A7 TNF
4 inflammatory response GO:0006954 10.34 CRP IL17A IL1A IL1B MEFV NLRP3
5 innate immune response GO:0045087 10.3 CAMP CRP IL17A LCN2 MEFV NLRP3
6 Notch signaling pathway GO:0007219 10.28 IL17A NCSTN PSEN1 PSENEN
7 positive regulation of JNK cascade GO:0046330 10.26 IL1A IL1B NOD2 TNF
8 positive regulation of MAP kinase activity GO:0043406 10.22 TNF PSEN1 NOD2 IL1B
9 cellular response to lipopolysaccharide GO:0071222 10.22 CAMP IL1A IL1B NLRP3 NOD2 TNF
10 positive regulation of tumor necrosis factor production GO:0032760 10.21 PSEN1 NOD2 IL1A IL17A IFNG
11 regulation of insulin secretion GO:0050796 10.18 TNF IL1B IFNG
12 positive regulation of phagocytosis GO:0050766 10.17 IFNG IL1B NOD2 TNF
13 positive regulation of interleukin-12 production GO:0032735 10.16 IFNG IL17A NOD2
14 positive regulation of nitric oxide biosynthetic process GO:0045429 10.16 TNF IL1B IFNG
15 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.15 TNF IL1B IL1A
16 positive regulation of mitotic nuclear division GO:0045840 10.14 TNF IL1B IL1A
17 positive regulation of catalytic activity GO:0043085 10.14 PSENEN PSEN1 NCSTN
18 positive regulation of inflammatory response GO:0050729 10.13 IFNG IL1B MEFV NLRP3 TNF
19 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.12 TNF NOD2 IL17A
20 membrane protein ectodomain proteolysis GO:0006509 10.11 NCSTN PSEN1 PSENEN
21 positive regulation of cytokine production GO:0001819 10.11 TNF IL26 IL1B IL1A IFNG
22 positive regulation of osteoclast differentiation GO:0045672 10.1 TNF IL17A IFNG
23 positive regulation of chemokine production GO:0032722 10.09 TNF IL1B IFNG
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.08 TNF IL1B IFNG
25 defense response GO:0006952 10.07 TNF NOD2 NLRP3 CAMP
26 amyloid precursor protein catabolic process GO:0042987 10.06 PSENEN PSEN1 NCSTN
27 response to lipopolysaccharide GO:0032496 10.06 TNF S100A7 NOD2 IL1B IL1A GJB2
28 amyloid precursor protein metabolic process GO:0042982 10.03 PSENEN PSEN1 NCSTN
29 amyloid-beta formation GO:0034205 10.02 PSENEN PSEN1 NCSTN
30 positive regulation of stress-activated MAPK cascade GO:0032874 10.01 IL1A IL26 NOD2
31 Notch receptor processing GO:0007220 10.01 PSENEN PSEN1 NCSTN
32 positive regulation of immature T cell proliferation in thymus GO:0033092 10 IL1B IL1A
33 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 10 TNF NOD2
34 positive regulation of type 2 immune response GO:0002830 9.99 NOD2 NLRP3
35 positive regulation of fever generation GO:0031622 9.98 TNF IL1B
36 sequestering of triglyceride GO:0030730 9.97 TNF IL1B
37 pattern recognition receptor signaling pathway GO:0002221 9.97 NOD2 NLRP3 MEFV
38 positive regulation of nitrogen compound metabolic process GO:0051173 9.95 TNF IFNG
39 fever generation GO:0001660 9.95 IL1B IL1A
40 positive regulation of interleukin-6 production GO:0032755 9.93 TNF NOD2 IL1B IL1A IL17A IFNG
41 positive regulation of vitamin D biosynthetic process GO:0060557 9.92 TNF IFNG
42 acute inflammatory response GO:0002526 9.91 TNF NLRP3 IL1A
43 cellular response to peptidoglycan GO:0071224 9.89 NOD2 NLRP3 CAMP
44 astrocyte activation GO:0048143 9.86 IFNG IL1B PSEN1 TNF
45 detection of biotic stimulus GO:0009595 9.81 NOD2 NLRP3
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.8 TNF IL1B IFNG
47 positive regulation of interleukin-1 beta production GO:0032731 9.73 TNF NOD2 NLRP3 MEFV IL17A IFNG
48 defense response to Gram-positive bacterium GO:0050830 9.4 TNF NOD2 NLRP3 IL1B IL17A CRP

Molecular functions related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.4 TNF IL26 IL1B IL1A IL17A IFNG
Sources

Sources for Hidradenitis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....